Who Paid My Doc
Long-Term Extension Study (Atdvance) to Evaluate the Safety and Effica
Research payments
$450,988
Through program year 2025, $450,988 in research payments was reported against Long-Term Extension Study (Atdvance) to Evaluate the Safety and Effica, across 165 payments, paid by GlaxoSmithKline, LLC..
- Paid by
- GlaxoSmithKline, LLC.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
2 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | Research | $267,750 | 124 |
| 2024 | Research | $183,238 | 41 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Kevin Donnelly Westerville, OH Named on 65 payments
- Gerald Slagel Fayetteville, GA Named on 17 payments
- Jessica Bernstein Naples, FL Named on 16 payments
- Vivian Laquer Orange, CA Named on 14 payments
- Jany Sanchez Homestead, FL Named on 7 payments
- Ali Moiin Livonia, MI Named on 6 payments
- Emily Prosise West Lake Hills, TX Named on 5 payments
- Joseph Howe Thomasville, GA Named on 5 payments
- Michael Peterson Scottsdale, AZ Named on 5 payments
- Neil Sadick Staten Island, NY Named on 4 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.